GlassScriptPhysician profile
Shilpi Khosla
NPI 1114922655
$3,764.80
in general payments reported to CMS, 2019-2025
37 companies · $675 in 2025
The $675 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $488 · 2020: $108 · 2021: $268 · 2022: $370 · 2023: $893 · 2024: $964 · 2025: $675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,531.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,101.45 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $331.93 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $227.37 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $196.14 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Amarin Pharma, INC. | $189.59 | 2019-2021 | |
| Abbvie INC. | $177.39 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $168.54 | 2021-2024 | Eliquis |
| Pfizer INC. | $148.35 | 2023-2025 | |
| Janssen Pharmaceuticals, INC | $147.39 | 2019-2022 | |
| Sumitomo Pharma America, INC. | $113.90 | 2023-2024 | Gemtesa |
| Dexcom, INC. | $81.44 | 2023-2025 | Dexcom G6 Transmitter |
| Abbott Laboratories | $77.20 | 2021-2023 | Freestyle Libre 3 |
| Amgen INC. | $68.44 | 2021-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $64.07 | 2019-2025 | Jardiance, Synjardy |
| Bayer Healthcare Pharmaceuticals INC. | $62.40 | 2022-2025 |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shilpi Khosla listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.